Evidence map›Paper›PMID 29654411›Full record

ArticleDrug delivery and translational research2018

Ciprofloxacin-lidocaine-based hydrogel: development, characterization, and in vivo evaluation in a second-degree burn model.

María Florencia Sanchez, Susana Andrea Breda, Elio Andrés Soria, Luis Ignacio Tártara, Rubén Hilario Manzo, María Eugenia Olivera

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Development ofRSC advances · 2024
    Article
  5. Sprayable ciprofloxacin-loaded poloxamer hydrogels for wound infection treatment.Journal of drug delivery science and technology · 2023
    Article
  6. Article
  7. Article
  8. Functional Hydrogel Dressings for Treatment of Burn Wounds.Frontiers in bioengineering and biotechnology · 2021
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

María Florencia SanchezUnidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA)-CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, 5000, Córdoba, Argentina.
Susana Andrea BredaFarmacia Central, Hospital Nacional de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Elio Andrés SoriaInstituto de Investigaciones en Ciencias de la Salud (INICSA)-CONICET and Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Luis Ignacio TártaraUnidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA)-CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, 5000, Córdoba, Argentina.
Rubén Hilario ManzoUnidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA)-CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, 5000, Córdoba, Argentina.
María Eugenia OliveraUnidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA)-CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, 5000, Córdoba, Argentina. meoliver@fcq.unc.edu.ar.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARUniversidad Nacional de Córdoba · AR

Funding

Consejo Nacional de Investigaciones Científicas y Técnicas PIP 2013-2015Fondo para la Investigación Científica y Tecnológica PICT 0173Universidad Nacional de Córdoba, SECYT-UNC 162/12
6 · The paper itself

Abstract

The purpose of this work was to develop an effective carbomer hydrogel to be used to treat second-degree burns that combined ciprofloxacin and lidocaine (CbCipLid hydrogel). Its antibiotic and anesthetic efficacy and the physical and chemical properties of the CbCipLid hydrogel (release rate and kinetics, rheology, appearance, and drug content) were evaluated both before and after a sterilization cycle and also after 6 months of storage. For the in vivo studies, second-degree burns were developed in a rat model. Animals were divided into three groups: CbCipLid hydrogel, silver sulfadiazine cream (reference), and carbomer hydrogel (as control). The treatments were applied daily for 21 days, and the healing was monitored by macroscopic observation and histologic evaluation. The anesthetic effect was evaluated through the corneal touch threshold in a rabbit eye model. The CbCipLid hydrogel obtained is transparent and allows the loading of ciprofloxacin above its solubility at a neutral pH, with a rheology which is convenient for topical administration. Its physical and chemical properties remained unchanged after sterilization and for at least six additional months. Both ciprofloxacin and lidocaine are reversibly released from the CbCipLid hydrogel with a kinetics fitting the Higuchi model. The presence of a biologic-like fluid increased the rate of drug delivery through an ionic exchange mechanism. Treatment with the CbCipLid hydrogel decreased the wound-healing period, compared with the reference, and was associated with a greater number of fibroblasts and a faster rate of epithelialization and dermis reconstruction. These differences were assigned to the moist environment provided by the hydrogel and also to the presence of a therapeutic concentration of ciprofloxacin. Moreover, CbCipLid hydrogel provides an immediate anesthetic effect, which is significantly more intense than that of the reference. Based on these results, it is believed that the CbCipLid hydrogel could be a potential candidate in the prophylaxis/treatment of second-degree burns.

Indexed as

Administration, TopicalAnimalsBurnsCiprofloxacinDisease Models, AnimalHydrogelsLidocaineMaleRabbitsRheologyTreatment OutcomeWound HealingCiprofloxacinHydrogelsLidocaineAesthesiometric evaluationBirefringencePainPolymeric drug delivery systemsRheologySkin

Identifiers

PMID29654411
OpenAlexW2797182038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.